Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H22O11 |
| Molecular Weight | 342.297 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@](O[C@]1([H])O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)([C@H](O)CO)[C@H](O)[C@@H](O)C=O
InChI
InChIKey=DKXNBNKWCZZMJT-JVCRWLNRSA-N
InChI=1S/C12H22O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h1,4-12,14-21H,2-3H2/t4-,5+,6+,7+,8-,9-,10+,11+,12-/m0/s1
| Molecular Formula | C12H22O11 |
| Molecular Weight | 342.297 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Lactose is the most important carbohydrate in the milk of most species. Its biosynthesis takes place in the mammary gland. The molecular structures of α- and β -lactose differ in the orientation of a hydrogen- and a hydroxyl group on carbon atom no.1 in the glucose moiety. Both forms change into one another continuously. At room temperature, the equilibrium results in a ratio of about 40% α-lactose and 60% β-lactose. The fact that two forms of lactose exist which differ in molecular structure has profound effects on various properties of lactose such as crystallization behavior, crystal morphology, solid-state properties, and solubility. The intestine does not actively absorb lactose unless it is split into its two-monosaccharide components, i.e. glucose and galactose. This hydrolysis of lactose is affected by the enzyme lactase, which is produced by the epithelium cells in the brush-border of the small intestine. Thus, the capacity of mammals to digest lactose is dependent on the lactase activity in the intestine. The maximum activity of the enzyme occurs shortly after birth and declines during the weaning period, after which it remains at a relatively constant level. Genetically determined factors governing residual lactase activity also exist. Individuals having low lactase activity are called lactose malabsorbers. Lactose intolerance is a condition in which people have symptoms due to the decreased ability to digest lactose. The principal symptom of lactose intolerance is an adverse reaction to products containing lactose (primarily milk), including abdominal bloating and cramps, flatulence, diarrhea, nausea, borborygmi, and vomiting (particularly in adolescents). These appear one-half to two hours after consumption.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P09848 Gene ID: 3938.0 Gene Symbol: LCT Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28426286 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Lactase non-persistent genotype distribution in Italy. | 2017-09 |
|
| Lactase Non-persistence and Lactose Intolerance. | 2017-05 |
|
| Blockage of Galectin-receptor Interactions by α-lactose Exacerbates Plasmodium berghei-induced Pulmonary Immunopathology. | 2016-08-24 |
|
| Abrasive water jet cutting as a new procedure for cutting cancellous bone--in vitro testing in comparison with the oscillating saw. | 2004-11-15 |
|
| Investigations into the use of pregelatinised starch to develop powder-filled hard capsules. | 2004-11-05 |
|
| Aerosolisation of beclomethasone dipropionate using spray dried lactose/polyethylene glycol carriers. | 2004-11 |
|
| Compaction of crystallographic forms of pharmaceutical granular lactoses. II. Compacts mechanical properties. | 2004-11 |
|
| Compaction of crystallographic forms of pharmaceutical granular lactoses. I. Compressibility. | 2004-11 |
|
| Approaches to determine the enthalpy of crystallisation, and amorphous content, of lactose from isothermal calorimetric data. | 2004-10-13 |
|
| The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy. | 2004-09 |
|
| Role of excipients in hydrate formation kinetics of theophylline in wet masses studied by near-infrared spectroscopy. | 2004-09 |
|
| Comparison of torque measurements and near-infrared spectroscopy in characterization of a wet granulation process. | 2004-09 |
|
| Generation of furosine and color in infant/enteral formula-resembling systems. | 2004-08-25 |
|
| Synthesis and hemolytic activity of some hederagenin diglycosides. | 2004-08 |
|
| Ab initio structure determination of the hygroscopic anhydrous form of alpha-lactose by powder X-ray diffraction. | 2004-08 |
|
| Single-step granulation/tabletting of different grades of lactose: a comparison with high shear granulation and compression. | 2004-07 |
|
| Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets. | 2004-07 |
|
| Endotoxin testing in inhalation grade lactose-a useful quality parameter? | 2004-05-04 |
|
| The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers. | 2004-05-04 |
|
| Melt pelletization with polyethylene glycol in a rotary processor. | 2004-05-04 |
|
| Quantifying low amorphous or crystalline amounts of alpha-lactose-monohydrate using X-ray powder diffraction, near-infrared spectroscopy, and differential scanning calorimetry. | 2004-05 |
|
| Twin screw granulation as a simple and efficient tool for continuous wet granulation. | 2004-04-01 |
|
| The 3D model: explaining densification and deformation mechanisms by using 3D parameter plots. | 2004-04 |
|
| Energy-based analysis of milling alpha-lactose monohydrate. | 2004-04 |
|
| Use of whey ultrafiltrate as a substrate for production of carotenoids by the yeast Rhodotorula rubra. | 2004-03 |
|
| Alternative sugars as potential carriers for dry powder inhalations. | 2004-02-11 |
|
| Characterization and taste-masking evaluation of acetaminophen granules: comparison between different preparation methods in a high-shear mixer. | 2004-02 |
|
| Demographic and health-related correlates of herbal and specialty supplement use. | 2004-01 |
|
| Visualization of the crystallization of lactose from the amorphous state. | 2004-01 |
|
| Moisture-induced surface crystallization of spray-dried amorphous lactose particles studied by atomic force microscopy. | 2004-01 |
|
| Glucose transport in lactation. | 2004 |
|
| Cryopreservation of spermatozoa from closed colonies, and inbred, spontaneous mutant, and transgenic strains of rats. | 2003-12 |
|
| A novel technique for imaging film coating defects in the film-core interface and surface of coated tablets. | 2003-11 |
|
| Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States. | 2003-10 |
|
| Physiological studies of Escherichia coli strain MG1655: growth defects and apparent cross-regulation of gene expression. | 2003-09 |
|
| Carotenoid production by lactoso-negative yeasts co-cultivated with lactic acid bacteria in whey ultrafiltrate. | 2003-08-27 |
|
| In vitro nutritional requirements and metabolic products of pathogenic and nonpathogenic strains of Cryptobia salmositica: essential carbohydrates and amino acids. | 2003-08-15 |
|
| Studies on the preparation of chitosan microcarriers cross-linked by oxidized lactose and culture of primary hepatocytes. | 2003-08 |
|
| The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer. | 2003-06-18 |
|
| The influence of carrier and drug morphology on drug delivery from dry powder formulations. | 2003-05-12 |
|
| The relationship between granule growth mechanism, amount of liquid binder added and properties of the wet powder mass determined using a split bed shear tester. | 2003-05-12 |
|
| Nutritional requirements of Pochonia chlamydospora and ARF18, fungal parasites of nematode eggs. | 2003-05 |
|
| Formulation design of carbamazepine fast-release tablets prepared by melt granulation technique. | 2003-04-30 |
|
| Quantitative determination of crystallinity of alpha-lactose monohydrate by Near Infrared Spectroscopy (NIRS). | 2003-04-30 |
|
| Influence of inverse gas chromatography measurement conditions on surface energy parameters of lactose monohydrate. | 2003-04-30 |
|
| Effect of aeration on the production of carotenoid pigments by Rhodotorula rubra-lactobacillus casei subsp. casei co-cultures in whey ultrafiltrate. | 2003-04-25 |
|
| Staphylococcus equorum subsp. linens, subsp. nov., a starter culture component for surface ripened semi-hard cheeses. | 2003-03 |
|
| Development of agglomerated directly compressible diluent consisting of brittle and ductile materials. | 2003 |
|
| Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets. | 2001-06-09 |
|
| Identification and synthesis of a novel 15 kDa beta-galactoside-binding lectin in human leukocytes. | 1992-08 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28421381
presence lactose in the food
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9237942
There was evaluated the capability of colonic bacteria to ferment lactose and the ability of L. acidophilus to modify lactose fermentation by the colonic microflora in vitro. An anaerobic continuous culture was established and inoculated with fresh samples of human feces. Lactose infusion was maintained at 25 g/d and pH at 6.7. L. acidophilus strain LA-1 (1.5 x 10(10) cells) was introduced into the fermenter on d 0 or added daily on d 0 through 4. The control was the continuous culture without the addition of lactobacilli. Rapid adaptation of colonic bacteria to lactose occurred within 1-2 d, with a significant decrease in lactose concentration and increase in beta-galactosidase activity, and lactose concentrations fell below 3 mmol/L by d 7.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 13:13:51 GMT 2025
by
admin
on
Wed Apr 02 13:13:51 GMT 2025
|
| Record UNII |
3SY5LH9PMK
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C68472
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3SY5LH9PMK
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
C74579
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
DTXSID2023193
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
m6662
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | Merck Index | ||
|
3037558
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
7962
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
3SY5LH9PMK
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
63-42-3
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
100000077075
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
1307662
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | RxNorm | ||
|
1356676
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
ANHYDROUS LACTOSE
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless. Solubility: Freely but slowly soluble in water; very slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Tablet and capsule diluent. Storage: Lactose should be kept in a well-closed container.Labelling: The designation on the container of Lactose should state whether it is the monohydrate or the anhydrous form. Additional information: Attention should be paid to the microbiological purity, since Lactose is of natural origin. | ||
|
36219
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
DB04465
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
200-559-2
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
CHEMBL417016
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY | |||
|
16984-38-6
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
ALTERNATIVE | |||
|
SUB14318MIG
Created by
admin on Wed Apr 02 13:13:51 GMT 2025 , Edited by admin on Wed Apr 02 13:13:51 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|